Association of xanthine oxidase inhibitors and statins and use thereof

摘要

NZ 603397 The disclosure relates to a combination of active principles, i.e. of a xanthine oxidase inhibitor: febuxostat with one or more HMG CoA reductase inhibitors belonging to the class of statins selected from the group comprising: atorvastatin, cerivastatin, fluvastatin, levostatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said active principles, for use in a human or veterinary therapeutic treatment, and methods for the preparation thereof. These compositions are suitable and effective in the treatment of hypercholesterolemia, alone or in association with hyperuricemia or to other disorders in the clinical context of the metabolic syndrome.